The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.
about
Novel drugs that target the metabolic reprogramming in renal cell cancerNew strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncologyCancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapiesA phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPTStructural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferaseSynergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenograftsNAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophagesMetabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cellsStructural basis for resistance to diverse classes of NAMPT inhibitorsCatastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis.Characterization of NAD uptake in mammalian cells.Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.New function for Escherichia coli xanthosine phophorylase (xapA): genetic and biochemical evidences on its participation in NAD(+) salvage from nicotinamide.Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferaseDiscovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT.NAD+ levels control Ca2+ store replenishment and mitogen-induced increase of cytosolic Ca2+ by Cyclic ADP-ribose-dependent TRPM2 channel gating in human T lymphocytes.Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cellsDependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618How to live long and prosper: autophagy, mitochondria, and aging.Regulation of inflammatory cytokine expression in pulmonary epithelial cells by pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism.Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.MC-PPEA as a new and more potent inhibitor of CLP-induced sepsis and pulmonary inflammation than FK866.Inhibition of Nicotinamide Phosphoribosyltransferase Induces Apoptosis in Estrogen Receptor-Positive MCF-7 Breast Cancer Cells.Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.Physiological and pathophysiological roles of NAMPT and NAD metabolism.Crystal structure-based comparison of two NAMPT inhibitors.Intracellular NAD+ levels are associated with LPS-induced TNF-α release in pro-inflammatory macrophages.
P2860
Q26740187-E2E81BF3-3418-4EFA-955E-23B0B52CDACBQ26745678-B5755B1A-A623-4ED0-BD88-CFD2BFE82F3AQ26823118-D0A7CA94-1FB8-49A6-A094-680581BAFBFBQ27656939-72719FAB-5732-48CF-B1BE-60015CF6C0D7Q27690154-A272AA8A-3E1F-460F-AD18-148388424CEDQ28476348-A07CF811-5E35-4637-868E-58B236E384A7Q28484852-4D2A9D1C-869D-48B4-84A9-ECBFCFBF9629Q28538761-63757D0A-632F-49AC-928D-6BC451C56351Q28542558-7506C30D-E78F-434C-BB14-79F183A3FF4DQ28543568-513E9782-7213-4B1B-89FC-084F674E63CFQ30912415-5528B5F1-4B59-4110-A700-A08904D1DFBEQ33422176-55B1FB3B-01D4-41FE-AD59-E27BE37D05E2Q33878859-437FD19E-6EBD-445E-AC51-EE1B4538F95BQ34009257-15B1CA89-C438-40D4-9E67-D12B68FBE774Q34103687-38257210-E013-4DFB-9156-A5ADD4135983Q34328772-F49D4A8E-425A-4373-BD80-979207053720Q34482044-22B88930-2B25-4D7A-93E0-AEC012847F6DQ35030829-71F956F5-7BDD-4D40-A73F-E845606CFB08Q35088919-A743A0EC-D1F6-407F-AA97-1154DF1ADB50Q35652041-98FCC0EB-6DD8-4056-89C9-186843A88EEEQ35727985-2F54FD55-AFE2-4328-ABDA-41EC54D17217Q36033195-A3E15975-816B-414D-89A1-DB87969D1663Q36579595-A1B2298D-40CC-4862-944D-3AD54A2F0794Q36771997-0D4F2C9D-0373-41F9-915C-57E2EB744875Q37098847-7FA94522-20B2-4EF0-8EFA-2125BC964788Q37151029-FF8D777B-BEAF-4507-9AF2-EA6F5652D99CQ37285546-9007571D-9A98-4585-89F6-29288D76B640Q37300834-DDD278F7-ED5A-4CB1-8D4A-A1D0B27C36D0Q37448001-E8897E42-4BCD-443D-B5EA-C533490C8969Q37448050-20C58E7E-8F11-49D6-8B5A-FA87E7CCA57BQ37619827-92DC92C3-B34B-421C-BD6B-F3044FB28C9FQ37626233-E4D09D14-F3EB-4DDB-A112-C2D67DFB68C1Q37691630-25FDC9F3-285F-4D1C-8427-D4E121A3CADDQ37735953-707F9BF8-D1C0-45A5-8A6A-F611CAF5704BQ37745422-8B5E0673-817B-4332-B402-691E71E1A31AQ38005192-61B1C8F3-387C-4D3F-A5C4-5E9B5321B7A2Q38405687-739A0392-D4B3-42AC-8C48-CC0C7EE4AEE9Q38555243-1E737460-E207-44B7-8A09-612F2B4E03B1Q38635017-7B0E530B-934F-44D4-BBD5-330903F40072Q38668587-FA3A770E-9E7F-41A3-BF54-599681B3ABFD
P2860
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The pharmacokinetics, toxiciti ...... eotide biosynthesis inhibitor.
@ast
The pharmacokinetics, toxiciti ...... eotide biosynthesis inhibitor.
@en
type
label
The pharmacokinetics, toxiciti ...... eotide biosynthesis inhibitor.
@ast
The pharmacokinetics, toxiciti ...... eotide biosynthesis inhibitor.
@en
prefLabel
The pharmacokinetics, toxiciti ...... eotide biosynthesis inhibitor.
@ast
The pharmacokinetics, toxiciti ...... eotide biosynthesis inhibitor.
@en
P2093
P1476
The pharmacokinetics, toxiciti ...... eotide biosynthesis inhibitor.
@en
P2093
Axel-Rainer Hanauske
Ellen Hollywood
Konrad Burk
Kyle Holen
P2888
P356
10.1007/S10637-007-9083-2
P577
2007-10-09T00:00:00Z
P6179
1036949014